Soluble CD70

A novel immunotherapeutic agent for experimental glioblastoma: Laboratory investigation

James Miller, Guenter Eisele, Ghazaleh Tabatabai, Steffen Aulwurm, Gabriele Von Kürthy, Lothar Stitz, Patrick Roth, Michael Weller

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Object. Given the overall poor outcome with current treatment strategies in malignant gliomas, immunotherapy has been considered a promising experimental approach to glioblastoma for more than 2 decades. A cell surface molecule, CD70, may induce potent antitumor immune responses via activation of the costimulatory receptor CD27 expressed on immune effector cells. There is evidence that a soluble form of CD70 (sCD70) may exhibit biological activity, too. A soluble costimulatory ligand is attractive because it may facilitate immune activation and may achieve a superior tissue distribution. Methods. To test the antiglioma effect of sCD70, the authors genetically modified SMA-560 mouse glioma cells to secrete the extracellular domain of CD70. They assessed the immunogenicity of the transfected cells in cocultures with immune effector cells by the determination of immune cell proliferation and the release of interferon-γ. Syngeneic VM/Dk mice were implanted orthotopically with control or sCD70-releasing glioma cells to determine a survival benefit mediated by sCD70. Depletion studies were performed to identify the cellular mediators of prolonged survival of sCD70-releasing glioma-bearing mice. Results. The authors found that ectopic expression of sCD70 enhanced the proliferation and interferon-γ release of syngeneic splenocytes in vitro. More importantly, sCD70 prolonged the survival of syngeneic VM/Dk mice bearing intracranial SMA-560 gliomas. The survival rate at 60 days increased from 5 to 45%. Antibody-mediated depletion of CD8-positive T cells abrogates the survival advantage conferred by sCD70. Conclusions. These data suggest that sCD70 is a potent stimulator of antiglioma immune responses that depend critically on CD8-positive T cells. Soluble CD70 could be a powerful adjuvant for future immunotherapy trials for glioblastoma.

Original languageEnglish
Pages (from-to)280-285
Number of pages6
JournalJournal of Neurosurgery
Volume113
Issue number2
DOIs
StatePublished - Aug 2010

Fingerprint

Glioblastoma
Glioma
Immunotherapy
Interferons
T-Lymphocytes
Tissue Distribution
Coculture Techniques
Cell Survival
Cell Proliferation
Ligands
Antibodies

Keywords

  • Glioma
  • Immunotherapy
  • SMA-560
  • Soluble CD70
  • T cell

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Soluble CD70 : A novel immunotherapeutic agent for experimental glioblastoma: Laboratory investigation. / Miller, James; Eisele, Guenter; Tabatabai, Ghazaleh; Aulwurm, Steffen; Von Kürthy, Gabriele; Stitz, Lothar; Roth, Patrick; Weller, Michael.

In: Journal of Neurosurgery, Vol. 113, No. 2, 08.2010, p. 280-285.

Research output: Contribution to journalArticle

Miller, J, Eisele, G, Tabatabai, G, Aulwurm, S, Von Kürthy, G, Stitz, L, Roth, P & Weller, M 2010, 'Soluble CD70: A novel immunotherapeutic agent for experimental glioblastoma: Laboratory investigation', Journal of Neurosurgery, vol. 113, no. 2, pp. 280-285. https://doi.org/10.3171/2009.11.JNS09901
Miller, James ; Eisele, Guenter ; Tabatabai, Ghazaleh ; Aulwurm, Steffen ; Von Kürthy, Gabriele ; Stitz, Lothar ; Roth, Patrick ; Weller, Michael. / Soluble CD70 : A novel immunotherapeutic agent for experimental glioblastoma: Laboratory investigation. In: Journal of Neurosurgery. 2010 ; Vol. 113, No. 2. pp. 280-285.
@article{b6f78eab30a84d8fb0d64d97cf28d014,
title = "Soluble CD70: A novel immunotherapeutic agent for experimental glioblastoma: Laboratory investigation",
abstract = "Object. Given the overall poor outcome with current treatment strategies in malignant gliomas, immunotherapy has been considered a promising experimental approach to glioblastoma for more than 2 decades. A cell surface molecule, CD70, may induce potent antitumor immune responses via activation of the costimulatory receptor CD27 expressed on immune effector cells. There is evidence that a soluble form of CD70 (sCD70) may exhibit biological activity, too. A soluble costimulatory ligand is attractive because it may facilitate immune activation and may achieve a superior tissue distribution. Methods. To test the antiglioma effect of sCD70, the authors genetically modified SMA-560 mouse glioma cells to secrete the extracellular domain of CD70. They assessed the immunogenicity of the transfected cells in cocultures with immune effector cells by the determination of immune cell proliferation and the release of interferon-γ. Syngeneic VM/Dk mice were implanted orthotopically with control or sCD70-releasing glioma cells to determine a survival benefit mediated by sCD70. Depletion studies were performed to identify the cellular mediators of prolonged survival of sCD70-releasing glioma-bearing mice. Results. The authors found that ectopic expression of sCD70 enhanced the proliferation and interferon-γ release of syngeneic splenocytes in vitro. More importantly, sCD70 prolonged the survival of syngeneic VM/Dk mice bearing intracranial SMA-560 gliomas. The survival rate at 60 days increased from 5 to 45{\%}. Antibody-mediated depletion of CD8-positive T cells abrogates the survival advantage conferred by sCD70. Conclusions. These data suggest that sCD70 is a potent stimulator of antiglioma immune responses that depend critically on CD8-positive T cells. Soluble CD70 could be a powerful adjuvant for future immunotherapy trials for glioblastoma.",
keywords = "Glioma, Immunotherapy, SMA-560, Soluble CD70, T cell",
author = "James Miller and Guenter Eisele and Ghazaleh Tabatabai and Steffen Aulwurm and {Von K{\"u}rthy}, Gabriele and Lothar Stitz and Patrick Roth and Michael Weller",
year = "2010",
month = "8",
doi = "10.3171/2009.11.JNS09901",
language = "English",
volume = "113",
pages = "280--285",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "2",

}

TY - JOUR

T1 - Soluble CD70

T2 - A novel immunotherapeutic agent for experimental glioblastoma: Laboratory investigation

AU - Miller, James

AU - Eisele, Guenter

AU - Tabatabai, Ghazaleh

AU - Aulwurm, Steffen

AU - Von Kürthy, Gabriele

AU - Stitz, Lothar

AU - Roth, Patrick

AU - Weller, Michael

PY - 2010/8

Y1 - 2010/8

N2 - Object. Given the overall poor outcome with current treatment strategies in malignant gliomas, immunotherapy has been considered a promising experimental approach to glioblastoma for more than 2 decades. A cell surface molecule, CD70, may induce potent antitumor immune responses via activation of the costimulatory receptor CD27 expressed on immune effector cells. There is evidence that a soluble form of CD70 (sCD70) may exhibit biological activity, too. A soluble costimulatory ligand is attractive because it may facilitate immune activation and may achieve a superior tissue distribution. Methods. To test the antiglioma effect of sCD70, the authors genetically modified SMA-560 mouse glioma cells to secrete the extracellular domain of CD70. They assessed the immunogenicity of the transfected cells in cocultures with immune effector cells by the determination of immune cell proliferation and the release of interferon-γ. Syngeneic VM/Dk mice were implanted orthotopically with control or sCD70-releasing glioma cells to determine a survival benefit mediated by sCD70. Depletion studies were performed to identify the cellular mediators of prolonged survival of sCD70-releasing glioma-bearing mice. Results. The authors found that ectopic expression of sCD70 enhanced the proliferation and interferon-γ release of syngeneic splenocytes in vitro. More importantly, sCD70 prolonged the survival of syngeneic VM/Dk mice bearing intracranial SMA-560 gliomas. The survival rate at 60 days increased from 5 to 45%. Antibody-mediated depletion of CD8-positive T cells abrogates the survival advantage conferred by sCD70. Conclusions. These data suggest that sCD70 is a potent stimulator of antiglioma immune responses that depend critically on CD8-positive T cells. Soluble CD70 could be a powerful adjuvant for future immunotherapy trials for glioblastoma.

AB - Object. Given the overall poor outcome with current treatment strategies in malignant gliomas, immunotherapy has been considered a promising experimental approach to glioblastoma for more than 2 decades. A cell surface molecule, CD70, may induce potent antitumor immune responses via activation of the costimulatory receptor CD27 expressed on immune effector cells. There is evidence that a soluble form of CD70 (sCD70) may exhibit biological activity, too. A soluble costimulatory ligand is attractive because it may facilitate immune activation and may achieve a superior tissue distribution. Methods. To test the antiglioma effect of sCD70, the authors genetically modified SMA-560 mouse glioma cells to secrete the extracellular domain of CD70. They assessed the immunogenicity of the transfected cells in cocultures with immune effector cells by the determination of immune cell proliferation and the release of interferon-γ. Syngeneic VM/Dk mice were implanted orthotopically with control or sCD70-releasing glioma cells to determine a survival benefit mediated by sCD70. Depletion studies were performed to identify the cellular mediators of prolonged survival of sCD70-releasing glioma-bearing mice. Results. The authors found that ectopic expression of sCD70 enhanced the proliferation and interferon-γ release of syngeneic splenocytes in vitro. More importantly, sCD70 prolonged the survival of syngeneic VM/Dk mice bearing intracranial SMA-560 gliomas. The survival rate at 60 days increased from 5 to 45%. Antibody-mediated depletion of CD8-positive T cells abrogates the survival advantage conferred by sCD70. Conclusions. These data suggest that sCD70 is a potent stimulator of antiglioma immune responses that depend critically on CD8-positive T cells. Soluble CD70 could be a powerful adjuvant for future immunotherapy trials for glioblastoma.

KW - Glioma

KW - Immunotherapy

KW - SMA-560

KW - Soluble CD70

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=77955616955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955616955&partnerID=8YFLogxK

U2 - 10.3171/2009.11.JNS09901

DO - 10.3171/2009.11.JNS09901

M3 - Article

VL - 113

SP - 280

EP - 285

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 2

ER -